Immunotherapy Trial Suggests There’s Still A Lot to Learn
Recent news that cancer immunotherapies may exacerbate disease in some patients is a sobering reminder that there’s still much to learn about these new treatments. Columbia Univeristy Irving Medical Center Newsroom recently sat with cancer immunotherapy expert Pawel Muranski, MD, to discuss the state of cancer immunotherapy and how researchers and physicians should proceed. He says, “Cancer immunotherapy represents a new era in oncology, but we need to continue to do careful clinical evaluations before offering it to new groups of patients.”
Visit the CUIMC Newsroom to read the complete Q+A with Dr. Muranski, a member of the Herbert Irving Comprehensive Cancer Center and assistant professor of medicine and of pathology & cell biology at Columbia.